Genetic Heterogeneity of Undifferentiated Pleomorphic Sarcoma: Is There Potential for Targeted Therapy?

Simple Summary Despite advances in multitargeted anticancer drugs and personalized treatment approaches, the management of soft tissue sarcoma remains challenging. Among the most difficult subtypes to diagnose and treat with targeted therapies is UPS, owing to its high degree of genetic heterogeneity. This review summarizes recent findings on the genetics and epigenetics of this sarcoma subtype and discusses the potential application of various targeted therapies.

• Publication year

  2025

• Venue

  Cancers

• Publication date

  2025-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/cancers17223613PMID 41300979PMCID 12651473
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hyperactivated YAP1 is essential for sustainable progression of renal clear cell carcinoma

  2025cited by this paper
• Dual inhibition of BET and EP300 has antitumor activity in undifferentiated pleomorphic sarcomas and synergizes with ferroptosis induction

  2024cited by this paper
• Single-cell and spatial transcriptomics identify COL6A3 as a prognostic biomarker in undifferentiated pleomorphic sarcoma

  2024cited by this paper
• Undifferentiated Pleomorphic Sarcoma: A Case Report

  2024cited by this paper
• Dysregulation of miRNAs in Soft Tissue Sarcomas

  2024cited by this paper
• A Rare Case of Primary Hepatic Undifferentiated Pleomorphic Sarcoma: Exploring Cancer-related Gene Mutations

  2024cited by this paper
• Cell-cycle phase progression analysis identifies three unique phenotypes in soft tissue sarcoma

  2024cited by this paper
• Structural Variants in the SMC1A Gene Associated With Near‐Haploidy in Undifferentiated Pleomorphic Sarcomas

  2024cited by this paper
• Clinicopathological and genetic characterization of radiotherapy-induced undifferentiated pleomorphic sarcoma following breast cancer: a case series of three tumors and comprehensive literature review

  2024cited by this paper
• Successful pazopanib treatment of undifferentiated pleomorphic sarcoma with coamplification of PDGFRA, VEGFR2 and KIT: A case report

  2024cited by this paper
• Collagen modification remodels the sarcoma tumor microenvironment and promotes resistance to immune checkpoint inhibition

  2024cited by this paper
• ATRX guards against aberrant differentiation in mesenchymal progenitor cells

  2024cited by this paper
• Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma

  2024cited by this paper
• Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

  2024cited by this paper
• Retroperitoneal undifferentiated pleomorphic sarcoma with total nephrectomy: a case report and literature review

  2023cited by this paper
• Undifferentiated pleomorphic sarcoma of the pancreas with novel SARM1‐NTRK1 gene fusion and associated pancreatitis, panniculitis, and polyarthritis syndrome

  2023cited by this paper
• The Role of Macrophages in Sarcoma Tumor Microenvironment and Treatment

  2023cited by this paper
• Sex-dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma

  2023cited by this paper
• Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications

  2023cited by this paper
• Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade

  2023cited by this paper
• EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries

  2023cited by this paper
• Histological markers, sickle-shaped blood vessels, myxoid area, and infiltrating growth pattern help stratify the prognosis of patients with myxofibrosarcoma/undifferentiated sarcoma

  2023cited by this paper
• A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway

  2023cited by this paper
• Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need

  2023cited by this paper
• Vanished MDM2 amplification in multiple recurrences of an irradiated poorly differentiated sarcoma with amplified TRIO::TERT fusion gene

  2023cited by this paper
• Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma

  2023cited by this paper
• ALK-positive lung cancer: a moving target

  2023cited by this paper
• Immunohistochemical positive regulatory domain member 10 expression in soft tissue sarcomas.

  2022cited by this paper
• Exploiting LRRC15 as a Novel Therapeutic Target in Cancer

  2022cited by this paper
• Single-cell sequencing reveals the landscape of the tumor microenvironment in a skeletal undifferentiated pleomorphic sarcoma patient

  2022cited by this paper
• Comparative oncology reveals DNMT3B as a molecular vulnerability in undifferentiated pleomorphic sarcoma

  2022cited by this paper
• EML4-ALK rearrangement in primary malignant fibrous histiocytoma of the lung treated with alectinib: A case report

  2022cited by this paper
• A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma

  2022cited by this paper
• Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma

  2022cited by this paper
• Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

  2022cited by this paper
• Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy

  2022cited by this paper
• Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin

  2022cited by this paper
• Analysis of Multiple Drug Resistance Mechanism in Different Types of Soft Tissue Sarcomas: Assessment of the Expression of ABC-Transporters, MVP, YB-1, and Analysis of Their Correlation with Chemosensitivity of Cancer Cells

  2022cited by this paper
• First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

  2021cited by this paper
• Genomic Characterization of Radiation-Induced Intracranial Undifferentiated Pleomorphic Sarcoma

  2021cited by this paper
• Over-methylation of Histone H3 Lysines Is a Common Molecular Change Among the Three Major Types of Soft-tissue Sarcoma in Patient-derived Xenograft (PDX) Mouse Models

  2021cited by this paper
• Undifferentiated and dedifferentiated soft tissue neoplasms: Immunohistochemical surrogates for differential diagnosis.

  2021cited by this paper
• Surgical excision margins for fibrohistiocytic tumors, including atypical fibroxanthoma and undifferentiated pleomorphic sarcoma: a probability model based on a systematic review.

  2021cited by this paper
• Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.

  2021cited by this paper
• Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures

  2021cited by this paper
• Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition

  2021cited by this paper
• The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma

  2021cited by this paper
• Successful Multidisciplinary Treatment for Aggressive Primary Pulmonary Undifferentiated Pleomorphic Sarcoma

  2020cited by this paper
• Targeting glutamine metabolism slows soft tissue sarcoma growth

  2020cited by this paper
• TGFβ and Hippo Pathways Cooperate to Enhance Sarcomagenesis and Metastasis through the Hyaluronan-Mediated Motility Receptor (HMMR)

  2020cited by this paper
• Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival

  2020cited by this paper
• Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation

  2020cited by this paper
• PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials

  2020cited by this paper
• Genetic aberrations and molecular biology of cardiac sarcoma

  2020cited by this paper
• The Long Noncoding RNA NEAT1 Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways

  2020cited by this paper
• Mandibular undifferentiated pleomorphic sarcoma: Molecular analysis of a primary cell population

  2020cited by this paper
• Larotrectinib followed by selitrectinib in a novel DCTN1–NTRK1 fusion undifferentiated pleomorphic sarcoma

  2020cited by this paper
• Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma

  2020cited by this paper
• The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives

  2020influential reference
• High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies

  2020cited by this paper
• Cutaneous soft tissue tumors: diagnostically disorienting epithelioid tumors that are not epithelial, and other perplexing mesenchymal lesions

  2019cited by this paper
• Identification of Novel Fusion Transcripts in Undifferentiated Pleomorphic Sarcomas by Transcriptome Sequencing

  2019cited by this paper
• Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas

  2019cited by this paper
• The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma

  2019cited by this paper
• Undifferentiated pleomorphic sarcomas with PRDM10 fusions have a distinct gene expression profile

  2019cited by this paper
• TP53 in bone and soft tissue sarcomas.

  2019cited by this paper
• Multidisciplinary approach to rare primary cardiac sarcoma: a case report and review

  2019cited by this paper
• MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma

  2019cited by this paper
• A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)

  2019cited by this paper
• Spindle cell liposarcoma with a TRIO-TERT fusion transcript

  2019cited by this paper
• Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.

  2019cited by this paper
• Pleomorphic dermal sarcoma in a man with HIV: report with next-generation sequencing analysis and review of the atypical fibroxanthoma/pleomorphic dermal sarcoma spectrum.

  2019cited by this paper
• Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth

  2019cited by this paper
• YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.

  2018cited by this paper
• Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma

  2018cited by this paper
• Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma

  2018cited by this paper
• SNX-2112 Induces Apoptosis and Autophagy of Nara-H Cells

  2018cited by this paper
• A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report

  2018cited by this paper
• Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response

  2018cited by this paper
• YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma

  2018cited by this paper
• The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS‐like antigen 1

  2018cited by this paper
• Undifferentiated Pleomorphic Sarcoma Metastatic to the Orbit.

  2018cited by this paper
• Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone

  2018cited by this paper
• Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma

  2017cited by this paper
• The DNA methyltransferase family: a versatile toolkit for epigenetic regulation

  2017cited by this paper
• T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas

  2017cited by this paper
• PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma

  2017cited by this paper
• Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.

  2017cited by this paper
• TAZ and YAP are frequently activated oncoproteins in sarcomas

  2016cited by this paper
• Phosphorylation of STAT3 in Undifferentiated Pleomorphic Sarcoma Is Correlated with a Favorable Prognosis

  2016cited by this paper
• Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma

  2016cited by this paper
• RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas

  2016cited by this paper
• Recurrent TRIO Fusion in Nontranslocation–Related Sarcomas

  2016cited by this paper
• A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas

  2015cited by this paper
• Undifferentiated pleomorphic sarcoma with co-existence of KRAS/PIK3CA mutations.

  2015cited by this paper
• Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma

  2015cited by this paper
• Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome

  2015cited by this paper
• Recurrent PRDM10 Gene Fusions in Undifferentiated Pleomorphic Sarcoma

  2014cited by this paper
• An approach to pleomorphic sarcomas: can we subclassify, and does it matter?

  2014cited by this paper
• High IGF2 and FGFR3 are associated with tumour progression in undifferentiated pleomorphic sarcomas, but EGFR and FGFR3 mutations are a rare event

  2014cited by this paper

• No citing papers are available for this paper.